Deanne Randolph, MBA

CEO and Founder, Board Member

Deanne brings more than 20 years of experience translating innovation into patient impact. She began her career at Johnson & Johnson, Bayer, and Pfizer, where she led U.S., European and global brand teams across several therapeutic areas. She later founded Sante Group, a consultancy that supported pharmaceutical and biotech companies in developing launch strategies and expanding into global markets.

As founder and CEO of Lumigen Biotechnology, Deanne applies her commercialization expertise to advance targeted cancer therapies through the company’s NOVVA™ platform. She is recognized for her ability to connect scientific innovation with practical execution to bring transformative therapies to patients.

Deanne holds both a BA and an MBA from Wake Forest University.